Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Palma – page 7

371 clinical trials in Palma, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Palma at a glance
371
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

371 trials in Palma

Open in trial search

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Bullous impetigo+3

Recruiting

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Sponsor:Laboratorios Ojer Pharma S.L.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Ovarian cancer

Recruiting

Study on Sentinel Lymph Node Technique in Early-Stage Ovarian Cancer Using Pertechnetate (99mTc) Sodium, Human Serum Albumin, and Indocyanine Green

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:IIS La Fe

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Study of Acalabrutinib with R-CHOP for Patients with Untreated Mantle Cell Lymphoma in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Swiss Group for Clinical Cancer Research

Study of Tezepelumab Compared to Placebo in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Fundacion Geltamo

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Palma

What the registry says about research in the country

01 Neoplasms

The cancer research activity in Palma De Mallorca focuses on improving treatment options for multiple myeloma, relapsed refractory multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and advanced non-small cell lung cancer. These studies are designed to assess whether newer therapies can improve disease control and patient outcomes.

  • Relapsed and refractory multiple myeloma
  • Newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
  • Advanced non-small cell lung cancer with KRAS G12C mutation
  • Evaluating treatment effectiveness and disease response

Across these trials, researchers are comparing innovative approaches with existing care to better understand how to extend survival and deepen responses.

02 Cardiovascular Diseases

Clinical trial work in cardiovascular diseases is centered on primary prevention of atherosclerotic cardiovascular disease. The main goal is to see whether new preventive strategies can lower the risk of serious heart and vascular events in people at elevated risk.

  • Atherosclerotic cardiovascular disease prevention
  • Reducing major adverse cardiovascular events
  • Testing preventive treatment effectiveness

These studies aim to strengthen early prevention and support better long-term cardiovascular health.

03 Hemic and Lymphatic Diseases

This research area includes studies in hematologic cancers such as multiple myeloma, relapsed refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome. The focus is on testing therapies that may improve control of blood-related malignancies and deepen treatment responses.

  • Multiple myeloma and relapsed refractory disease
  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Assessing therapeutic benefit in blood cancers

Investigators are working to refine treatment strategies for patients with difficult-to-treat hematologic conditions.

04 Nervous System Diseases

Trials in nervous system diseases are exploring better ways to prevent and ease chronic postsurgical pain after inguinal hernia repair. The aim is to reduce the chance that short-term surgical pain becomes a lasting problem.

  • Chronic postsurgical pain
  • Pain after inguinal hernia repair
  • Improving postoperative symptom control

These studies focus on making recovery more comfortable and helping patients return to normal activity more smoothly.

05 Stomatognathic Diseases

Research in stomatognathic diseases is examining ways to prevent clinically relevant oral bleeding after tooth extraction in patients using direct oral anticoagulants or vitamin K antagonists. The purpose is to improve safety in everyday dental care for people on blood-thinning treatment.

  • Oral bleeding after tooth extraction
  • Patients treated with anticoagulants
  • Preventing postoperative hematomas

These studies aim to support safer dental procedures without compromising cardiovascular protection.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.